Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 5/20 | 0.38 |
| ▸ | SLC18A3 | Q16572 | 2/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.32 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.32 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5520665 | 0.89 | NOTUM (0.36) | SLC18A3 | |
| SCHEMBL5522854 | 0.89 | NOTUM (0.36) | SLC18A3 | |
| SCHEMBL707044 | 0.85 | HDAC4 (0.34) | RIPK1L3MBTL1 | |
| SCHEMBL2114467 | 0.80 | — | — | |
| SCHEMBL17104487 | 0.73 | RIPK1 (0.43) | RIPK1POLBSLC6A2SLC6A4SLC6A3 | |
| SCHEMBL3991385 | 0.72 | RIPK1 (0.41) | RIPK1POLBSLC6A2SLC6A4SLC6A3 | |
| SCHEMBL4099326 | 0.72 | RIPK1 (0.41) | RIPK1POLBSLC6A2SLC6A4SLC6A3 | |
| SCHEMBL4114277 | 0.72 | RIPK1 (0.41) | RIPK1POLBSLC6A2SLC6A4SLC6A3 | |
| SCHEMBL2800431 | 0.69 | RAB9A (0.37) | SLC18A3 | |
| SCHEMBL5025626 | 0.69 | RAB9A (0.37) | SLC18A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7683068-B2 | Hydroisoindoline tachykinin receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2010-03-23 | — | — | US | disclosed |
| US-7645790-B2 | Hydroisoindoline tachykinin receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2010-01-12 | — | — | US | disclosed |
| US-20090054462-A1 | Hydroisoindoline tachykinin receptor antagonists | MERCK SHARP & DOHME CORP. | 2009-02-26 | — | — | US | disclosed |
| US-20080280966-A1 | Hydroisoindoline Tachykinin Receptor Antagonists | VYNE THERAPEUTICS INC. (F/K/A MENLO THERAPEUTICS INC. AND SUCCESSOR-IN-INTEREST TO VYNE PHARMACEUTICALS LTD., F/K/A FOAMIX PHARMACEUTICALS LTD.) | 2008-11-13 | — | — | US | disclosed |
| US-7345083-B2 | Hydroisoindoline tachykinin receptor antagonists | MERCK & CO., INC. (US) | 2008-03-18 | — | — | US | disclosed |
| EP-1711465-B1 | HYDROISOINDOLINE TACHYKININ RECEPTOR ANTAGONISTS | MERCK & CO INC (US) | 2007-12-26 | — | — | EP | disclosed |
| US-20070161695-A1 | Hydroisoindoline tachykinin receptor antagonists | VYNE THERAPEUTICS INC. (F/K/A MENLO THERAPEUTICS INC. AND SUCCESSOR-IN-INTEREST TO VYNE PHARMACEUTICALS LTD., F/K/A FOAMIX PHARMACEUTICALS LTD.) | 2007-07-12 | — | — | US | disclosed |
| US-7217731-B2 | Hydroisoindoline tachykinin receptor antagonists | MERCK & CO., INC. (US) | 2007-05-15 | — | — | US | disclosed |
| EP-1711465-A1 | HYDROISOINDOLINE TACHYKININ RECEPTOR ANTAGONISTS | Merck & Co., Inc. (US) | 2006-10-18 | — | — | EP | disclosed |
| WO-2005073191-A1 | HYDROISOINDOLINE TACHYKININ RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 2005-08-11 | — | — | WO | disclosed |
| US-20050165083-A1 | Hydroisoindoline tachykinin receptor antagonists | VYNE THERAPEUTICS INC. (F/K/A MENLO THERAPEUTICS INC. AND SUCCESSOR-IN-INTEREST TO VYNE PHARMACEUTICALS LTD., F/K/A FOAMIX PHARMACEUTICALS LTD.) | 2005-07-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090054462-A1 | Hydroisoindoline tachykinin receptor antagonists | TACR1, TACR2, NPSR1 | RIPK1 3079/4885SLC18A3 221/4885L3MBTL1 4173/4885 |
| US-20050165083-A1 | Hydroisoindoline tachykinin receptor antagonists | TACR1, TACR2, NPSR1 | RIPK1 3079/4885SLC18A3 221/4885L3MBTL1 4173/4885 |
| US-20070161695-A1 | Hydroisoindoline tachykinin receptor antagonists | TACR1, TACR2, NPSR1 | RIPK1 3079/4885SLC18A3 221/4885L3MBTL1 4173/4885 |
| US-20080280966-A1 | Hydroisoindoline Tachykinin Receptor Antagonists | TACR1, TACR2, NPSR1 | RIPK1 3390/4885SLC18A3 223/4885L3MBTL1 4455/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.